Journal of Current Glaucoma Practice

Register      Login

VOLUME 16 , ISSUE 2 ( May-August, 2022 ) > List of Articles


Efficacy of the XEN45 Implant in Advanced to End-stage Glaucoma Patients

Isaac Hindi, Eran Berkowitz, Inbar Waizer, Beatrice Tiosano

Keywords : Advanced glaucoma, End-stage glaucoma, Hypotony, Needling, XEN45

Citation Information : Hindi I, Berkowitz E, Waizer I, Tiosano B. Efficacy of the XEN45 Implant in Advanced to End-stage Glaucoma Patients. J Curr Glaucoma Pract 2022; 16 (2):84-90.

DOI: 10.5005/jp-journals-10078-1364

License: CC BY-NC 4.0

Published Online: 30-08-2022

Copyright Statement:  Copyright © 2022; The Author(s).


Purpose: To report the efficacy of the XEN45 implant in advanced to end-stage glaucoma patients, after a 6 months follow-up. Methods: Retrospective, noncomparative electronic health record audit of patients who had undergone an XEN45 procedure. The main outcome measures were intraocular pressure (IOP) reduction and the number of antihypertensive medications. Secondary outcome measures were the rates of early postoperative complications. Complete and qualified success; failure and hypotony were defined according to the World Glaucoma Association guidelines (Shaarawy TM et al.). Needling rates and short-term complications were assessed and a subgroup analysis was performed. Results: A total of 39 eyes with advanced to end stage-glaucoma were included. Twenty eyes (51%) had undergone combined cataract surgery and 19 (49%), the XEN45 procedure alone. Mean IOP decreased from 19.67 ± 7.87 mm Hg to 13.18 ± 6.09 mm Hg; the number of medications decreased from a median use of 4 (IQR 2–5) to 0 (IQR 0–1). Complete success was achieved in 24 (61.5%) of the eyes, qualified success in 10 (25.6%), and failure in five (12.82%). Needling was required in 15 (38.46%) of the eyes at 6 months. Choroidal detachment occurred in eight (20.51%) eyes, numerical hypotony (IOP ≤ 5 mm Hg) at day 1 was noted in seven (17.95%) eyes with a full resolution by 2 weeks. Conclusion: In this short-term follow-up, we have seen that XEN45 is a viable, effective, and safe procedure utilized in advanced to end-stage glaucoma patients. Treating cases of significant hypotony using AC reformation with sulfur hexafluoride (SF6) is a safe and effective procedure.

PDF Share
  1. Tham Y-C, Li X, Wong TY, et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology 2014;121(11):2081–2090. DOI: 10.1016/j.ophtha.2014.05.013
  2. Kidd MN, O'Connor M. Progression of field loss after trabeculectomy: a five-year follow-up. Br J Ophthalmol 1985;69(11):827–831. DOI: 10.1136/bjo.69.11.827
  3. Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the early manifest glaucoma trial. Arch Ophthalmol 2002;120(10): 1268–1279. DOI: 10.1001/archopht.120.10.1268
  4. Saheb H, Ahmed IIK. Micro-invasive glaucoma surgery: current perspectives and future directions. Curr Opin Ophthalmol 2012;23(2):96–104. DOI: 10.1097/ICU.0b013e32834ff1e7
  5. Ansari E. An update on implants for minimally invasive glaucoma surgery (MIGS). Ophthalmol Ther 2017;6(2):233–241. DOI: 10.1007/s40123-017-0098-2
  6. Manasses DT, Au L. The new era of glaucoma micro-stent surgery. Ophthalmol Ther 2016;5(2):135–146. DOI: 10.1007/s40123-016-0054-6
  7. Sheybani A, Reitsamer H, Ahmed IIK. Fluid dynamics of a novel micro-fistula implant for the surgical treatment of glaucoma. Invest Ophthalmol Vis Sci 2015;56(8):4789–4795. DOI: 10.1167/iovs.15-16625
  8. Tan SZ, Walkden A, Au L. One-year result of XEN45 implant for glaucoma: efficacy, safety, and postoperative management. Eye (Lond) 2018;32(2):324–332. DOI: 10.1038/eye.2017.162
  9. Gregorio AD, Pedrotti E, Russo L, et al. Minimally invasive combined glaucoma and cataract surgery: clinical results of the smallest ab interno gel stent. Int Ophthalmol 2018;38(3):1129–1134. DOI: 10.1007/s10792-017-0571-x
  10. Pérez-Torregrosa VT, Olate-Pérez Á, Cerdà-Ibáñez M, et al. Combined phacoemulsification and XEN45 surgery from a temporal approach and 2 incisions. Arch Soc Esp Oftalmol 2016;91(9):415–421. DOI: 10.1016/j.oftal.2016.02.006
  11. Heidinger A, Schwab C, Lindner E, et al. A retrospective study of 199 xen45 stent implantations from 2014 to 2016. J Glaucoma 2019;28(1):75–79. DOI: 10.1097/IJG.0000000000001122
  12. Galal A, Bilgic A, Eltanamly R, et al. XEN glaucoma implant with Mitomycin C 1-year follow-up: result and complications. J Ophthalmol 2017;2017:5457246. DOI: 10.1155/2017/5457246
  13. Mansouri K, Guidotti J, Rao HL, et al. Prospective evaluation of standalone XEN gel implant and combined phacoemulsification-xen gel implant surgery: 1-year results. J Glaucoma 2018;27(2):140–147. DOI: 10.1097/IJG.0000000000000858
  14. Karimi A, Lindfield D, Turnbull A, et al. A multi-centre interventional case series of 259 ab-interno Xen gel implants for glaucoma, with and without combined cataract surgery. Eye (Lond) 2019;33(3):469–477. DOI: 10.1038/s41433-018-0243-8
  15. Reitsamer H, Sng C, Vera V, et al. Two-year results of a multicenter study of the ab interno gelatin implant in medically uncontrolled primary open-angle glaucoma. Graefes Arch Clin Exp Ophthalmol 2019;257(5):983–996. DOI: 10.1007/s00417-019-04251-z
  16. Fea AM, Bron AM, Economou MA, et al. European study of the efficacy of a cross-linked gel stent for the treatment of glaucoma. J Cataract Refract Surg 2020;46(3):441–450. DOI: 10.1097/j.jcrs.0000000000000065
  17. Shaarawy TM, Sherwood MB, Grehn F. Guidelines on design and reporting of glaucoma surgical trials. World Glaucoma Association 2009:15–24.
  18. Laborda-Guirao T, Cubero-Parra JM, Hidalgo-Torres A. Efficacy and safety of XEN 45 gel stent alone or in combination with phacoemulsification in advanced open angle glaucoma patients: 1-year retrospective study. Int J Ophthalmol 2020;13:1250–1256. DOI: 10.18240/ijo.2020.08.11
  19. Hodapp E, Parrish RK II, Anderson DR: Clinical Decisions in Glaucoma. St. Louis, CV Mosby, 1993.
  20. Widder RA, Dietlein TS, Dinslage S, et al. The XEN45 gel stent as a minimally invasive procedure in glaucoma surgery: success rates, risk profile, and rates of re-surgery after 261 surgeries. Graefes Arch Clin Exp Ophthalmol 2018;256(4):765–771. DOI: 10.1007/s00417-018-3899-7
  21. Smith M, Charles R, Abdel-Hay A, et al. 1-year outcomes of the Xen45 glaucoma implant. Eye (Lond) 2019;33(5):761–766. DOI: 10.1038/s41433-018-0310-1
  22. Sheybani A, Dick HB, Ahmed IIK. Early clinical results of a novel ab interno gel stent for the surgical treatment of open-angle glaucoma. J Glaucoma 2016;25(7):e691–e696. DOI: 10.1097/IJG.0000000000000352
  23. Gedde SJ, Schiffman JC, Feuer WJ, et al. Treatment outcomes in the tube versus trabeculectomy study after one year of follow-up. Am J Ophthalmol 2007;143(1):9–22. DOI: 10.1016/j.ajo.2006.07.020
  24. Wilson MR, Mendis U, Smith SD, et al. Ahmed glaucoma valve implant vs trabeculectomy in the surgical treatment of glaucoma: a randomized clinical trial. Am J Ophthalmol 2000;130(3):267–273. DOI: 10.1016/s0002-9394(00)00473-6
  25. Dar N, Sharon T, Hecht I, et al. Efficacy and safety of the ab interno gelatin stent in severe pseudoexfoliation glaucoma compared to non-pseudoexfoliation glaucoma at 6 months. Eur J Ophthalmol 2020;30(5):1028–1033. DOI: 10.1177/1120672119848277
  26. Kalina AG, Kalina PH, Brown MM. XEN® gel stent in medically refractory open-angle glaucoma: results and observations after one year of use in the United States. Ophthalmol Ther 2019;8(3):435–446. DOI: 10.1007/s40123-019-0192-8
  27. Hengerer FH, Kohnen T, Mueller M, et al. Ab interno gel implant for the treatment of glaucoma patients with or without prior glaucoma surgery: 1-year results. J Glaucoma 2017;26(12):1130–1136. DOI: 10.1097/IJG.0000000000000803
  28. Grover DS, Flynn WJ, Bashford KP, et al. Performance and safety of a new ab interno gelatin stent in refractory glaucoma at 12 months. Am J Ophthalmol 2017;183:25–36. DOI: 10.1016/j.ajo.2017.07.023
  29. Fea AM, Spinetta R, Cannizzo PML, et al. Evaluation of bleb morphology and reduction in IOP and glaucoma medication following implantation of a novel gel stent. J Ophthalmol 2017;2017:9364910. DOI: 10.1155/2017/9364910
  30. Schlenker MB, Gulamhusein H, Conrad-Hengerer I, et al. Efficacy, safety, and risk factors for failure of standalone ab interno gelatin microstent implantation versus standalone trabeculectomy. Ophthalmology 2017;124(11):1579–1588. DOI: 10.1016/j.ophtha.2017.05.004
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.